Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Garner, Jo Meagan ^a   Ellison, David W ^b   Finkelstein, David ^b   Ganguly, Debolina ^a   Du, Ziyun ^a   Sims, Michelle ^a   Yang, Chuan He ^a   Interiano, Rodrigo B ^a,b   Davidoff, Andrew M ^a,b   Pfeffer, Lawrence M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; STAT3 PROTEIN; UNCLASSIFIED DRUG; 3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; ANGPTL4 PROTEIN, HUMAN; PROTEIN BINDING; PYRIDINE DERIVATIVE; TYRPHOSTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CANCER SURVIVAL; CELL ADHESION; CELL HETEROGENEITY; CELL ISOLATION; CELL POPULATION; GENE EXPRESSION; GENOMICS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR SPHEROID; TUMOR XENOGRAFT; ANIMAL; BRAIN TUMOR; CANCER GRADING; CELL SEPARATION; DNA MICROARRAY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETICS; MALE; MESODERM; METABOLISM; MULTICELLULAR SPHEROID; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROMOTER REGION; SCID MOUSE; SUBCUTANEOUS TISSUE; SURVIVAL ANALYSIS; UPREGULATION; VASCULARIZATION;

ANGIOPOIETINS; ANIMALS; BRAIN NEOPLASMS; CELL ADHESION; CELL SEPARATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; GLIOBLASTOMA; HUMANS; MALE; MESODERM; MICE, SCID; NEOPLASM GRADING; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PYRIDINES; SPHEROIDS, CELLULAR; STAT3 TRANSCRIPTION FACTOR; SUBCUTANEOUS TISSUE; SURVIVAL ANALYSIS; TYRPHOSTINS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84957803452     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125838     Document Type: Article

References (50)

1. Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. Journal of neuro-oncology. 1998; 40(2):151-60. PMID: 9892097.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. PMID: 15758009.
3. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8): 2572-8. PMID: 10561324.
4. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. doi: 10.1016/j.ccr.2009.12.020 PMID: 20129251; PubMed Central PMCID: PMC2818769.
5. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21(21):2683-710. doi: 10.1101/gad. 1596707 PMID: 17974913.
6. p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain pathology. 1996; 6(3):217-23; discussion 23-4. PMID: 8864278.
7. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine. 2009; 360(8):765-73. doi: 10.1056/NEJMoa0808710 PMID: 19228619; PubMed Central PMCID: PMC2820383.
8. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006; 9(3):157-73. doi: 10.1016/j.ccr.2006.02.019 PMID: 16530701.
9. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002; 296(5569):920-2. doi: 10.1126/science.1068452 PMID: 11988578; PubMed Central PMCID: PMC3024710.
10. ClarkeMF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACRWorkshop on cancer stem cells. Cancer Res. 2006; 66(19):9339-44. Epub 2006/09/23. 0008-5472.CAN-06-3126 [pii] doi: 10.1158/0008-5472.CAN-06-3126 PMID: 16990346.
11. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. doi: 10.1016/j.cell.2008. 03.027 PMID: 18485877; PubMed Central PMCID: PMC2728032.
12. Marotta LL, Polyak K. Cancer stem cells: A model in the making. Current opinion in genetics & development. 2009; 19(1):44-50. doi: 10.1016/j.gde.2008.12.003 PMID: 19167210.
13. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005; 5(4):311-21. PMID: 15803157.
14. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17(10): 1253-70. PMID: 12756227.
15. Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, et al. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci. 2005; 8(6):723-9. PMID: 15908947.
16. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009; 4(6):568-80. Epub 2009/06/06. doi: 10.1016/j.stem.2009.03.014 PMID: 19497285.
17. Okochi-Takada E, Hattori N, Tsukamoto T, Miyamoto K, Ando T, Ito S, et al. ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis. Oncogene. 2014; 33(17):2273-8. doi: 10.1038/onc.2013. 174 PMID: 23686315.
18. Tan MJ, Teo Z, Sng MK, Zhu P, Tan NS. Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer Res. 2012; 10(6):677-88. doi: 10.1158/1541-7786.MCR-11-0519 PMID: 22661548.
19. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 2012; 14(3):315-25. doi: 10.1093/neuonc/nor209 PMID: 22156546; PubMed Central PMCID: PMC3280799.
20. Yang CH, Yue J, Pfeffer SR, Handorf CR, Pfeffer LM. MicroRNA miR-21 Regulates the Metastatic Behavior of B16 Melanoma Cells. J Biol Chem. 2011; 286(45):39172-8. Epub 2011/09/24. doi: 10.1074/jbc.M111.285098 PMID: 21940630.
21. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, et al. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 2007; 26(17): 2435-44. doi: 10.1038/sj.onc.1210031 PMID: 17043651.
22. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer. 2010; 102(11):1592-9. doi: 10.1038/sj.bjc. 6605691 PMID: 20461084; PubMed Central PMCID: PMC2883159.
23. Kong LY, Abou-Ghazal MK, Wei J, Chakraborty A, Sun W, Qiao W, et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008; 14(18):5759-68. doi: 10.1158/1078-0432.CCR-08-0377 PMID: 18794085; PubMed Central PMCID: PMC2583362.
24. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005; 102(16):5814-9. doi: 10.1073/pnas.0402870102 PMID: 15827123; PubMed Central PMCID: PMC556127.
25. Garner JM, Fan M, Yang CH, Du Z, Sims M, Davidoff AM, et al. Constitutive Activation of Signal Transducer and Activator of Transcription 3 (STAT3) and Nuclear Factor kappaB Signaling in Glioblastoma Cancer Stem Cells Regulates the Notch Pathway. J Biol Chem. 2013; 288(36):26167-76. doi: 10.1074/jbc.M113.477950 PMID: 23902772; PubMed Central PMCID: PMC3764819.
26. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9(5):391-403. PMID: 16697959.
27. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6): 442-54. doi: 10.1038/nrc822 PMID: 12189386.
28. Bhat KP, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell. 2013; 24(3):331-46. doi: 10.1016/j.ccr.2013.08.001 PMID: 23993863; PubMed Central PMCID: PMC3817560.
29. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochemical research. 2000; 25(9-10):1439-51. PMID: 11059815.
30. Kahn HJ, Marks A, Thom H, Baumal R. Role of antibody to S100 protein in diagnostic pathology. American journal of clinical pathology. 1983; 79(3):341-7. PMID: 6299096.
31. Hirokawa N, Hisanaga S, Shiomura Y. MAP2 is a component of crossbridges between microtubules and neurofilaments in the neuronal cytoskeleton: quick-freeze, deep-etch immunoelectron microscopy and reconstitution studies. The Journal of neuroscience: The official journal of the Society for Neuroscience. 1988; 8(8):2769-79. PMID: 3045269.
32. Marie Y, Sanson M, Mokhtari K, Leuraud P, Kujas M, Delattre JY, et al. OLIG2 as a specific marker of oligodendroglial tumour cells. Lancet. 2001; 358(9278):298-300. doi: 10.1016/S0140-6736(01)05499- X PMID: 11498220.
33. Xie Q, Thompson R, Hardy K, DeCamp L, Berghuis B, Sigler R, et al. A highly invasive human glioblastoma pre-clinical model for testing therapeutics. Journal of translational medicine. 2008; 6:77. doi: 10. 1186/1479-5876-6-77 PMID: 19055779; PubMed Central PMCID: PMC2645376.
34. Abdelzaher E. CNS Tumors Pathology-Glioblastoma Multiforme PathologyOutlines.com2013 [updated March 2012; cited 2014 March 15]. Availablehttp://www.pathologyoutlines.com/topic/cnstumorglioblastoma.html.
35. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010; 463(7279):318-25. doi: 10.1038/nature08712 PMID: 20032975.
36. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, et al. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One. 2010; 5(10): e13665. doi: 10.1371/journal.pone.0013665 PMID: 21060868; PubMed Central PMCID: PMC2965143.
37. Liu WM, Huang P, Kar N, Burgett M, Muller-Greven G, Nowacki AS, et al. Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy. PLoS One. 2013; 8(8): e70804. doi: 10.1371/journal.pone.0070804 PMID: 23936469; PubMed Central PMCID: PMC3732228.
38. Okamura T, Kurisu K, Yamamoto W, Takano H, Nishiyama M. NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy. Int J Oncol. 2000; 16(2):295-303. PMID: 10639573.
39. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncology. 2005; 7(2):122-33. doi: 10.1215/S1152851704001061 PMID: 15831231; PubMed Central PMCID: PMC1871893.
40. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006; 42(6):768-78. doi: 10.1016/j.ejca.2006.01.006 PMID: 16510280.
41. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000; 88(12):2887. PMID: 10870076.
42. Bonavia R, Inda MM, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: A social network. Cancer Res. 2011; 71(12):4055-60. doi: 10.1158/0008-5472.CAN-11-0153 PMID: 21628493; PubMed Central PMCID: PMC3117065.
43. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014; 344(6190):1396-401. doi: 10.1126/science.1254257 PMID: 24925914; PubMed Central PMCID: PMC4123637.
44. Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T, Koizumi F. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Molecular cancer. 2013; 12:31. doi: 10.1186/1476-4598-12-31 PMID: 23617883; PubMed Central PMCID: PMC3641008.
45. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. Epub 2002/04/18. doi: 10.1038/sj.onc.1205260 PMID: 11960372.
46. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. Epub 2003/09/18. doi: 10.1038/nrc1187nrc1187 [pii]. PMID: 13130303.
47. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, et al. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008; 14(24):8228-35. Epub 2008/12/18. doi: 10.1158/1078-0432.CCR-08-132914/24/8228 [pii]. PMID: 19088040; PubMed Central PMCID: PMC2605668.
48. Verine J, Lehmann-Che J, Soliman H, Feugeas JP, Vidal JS, Mongiat-Artus P, et al. Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma. PLoS One. 2010; 5(4):e10421. Epub 2010/05/11. doi: 10.1371/journal.pone.0010421 PMID: 20454689; PubMed Central PMCID: PMC2861680.
49. Zhu P, Goh YY, Chin HF, Kersten S, Tan NS. Angiopoietin-like 4: A decade of research. Biosci Rep. 2012; 32(3):211-9. Epub 2012/03/31. BSR20110102 [pii] doi: 10.1042/BSR20110102 PMID: 22458843.
50. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007; 67(20):9630-6. Epub 2007/10/19. doi: 10.1158/0008-5472.CAN-07-1243 PMID: 17942891.